Literature DB >> 7546361

Cerebral arterial spasm--a clinical review.

N W Dorsch1.   

Abstract

A review of the literature on cerebral vasospasm after aneurysmal subarachnoid haemorrhage (SAH) has shown that angiographic vasospasm occurs in 67.3% of cases when angiography is timed for the highest likelihood, and delayed ischaemic deficit or symptomatic vasospasm in 32.6%. The presence of vasospasm has a marked effect on overall outcome of SAH, and the outcome of delayed ischaemia itself is in about one-third death and in one-third permanent deficit. Management with fluid loading or induced hypertension and with calcium antagonists has been reported widely for both prevention and treatment, and can reduce the incidence and improve the outcome of vasospasm. Other forms of treatment including tissue plasminogen activator, aminosteroids and transluminal angioplasty also appear useful. In spite of these improved therapeutic possibilities, large numbers of patients are still being reported in whom no specific treatment is used.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7546361     DOI: 10.1080/02688699550041403

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  44 in total

1.  The safety and feasibility of continuous intravenous magnesium sulfate for prevention of cerebral vasospasm in aneurysmal subarachnoid hemorrhage.

Authors:  Abutaher M Yahia; Jawad F Kirmani; Adnan I Qureshi; Lee R Guterman; L Nelson Hopkins
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

2.  Delayed ischemic optic neuropathy after surgery on skull base meningiomas successfully treated with nimodipine and rheological therapy: report of two cases.

Authors:  E van Lindert; W Hassler; A D Saletta
Journal:  Skull Base Surg       Date:  2000

3.  Effect of nitrous oxide use on long-term neurologic and neuropsychological outcome in patients who received temporary proximal artery occlusion during cerebral aneurysm clipping surgery.

Authors:  Jeffrey J Pasternak; Diana G McGregor; William L Lanier; Darrell R Schroeder; Deborah A Rusy; Bradley Hindman; William Clarke; James Torner; Michael M Todd
Journal:  Anesthesiology       Date:  2009-03       Impact factor: 7.892

Review 4.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  Heme oxygenase-1 gene induction as an intrinsic regulation against delayed cerebral vasospasm in rats.

Authors:  H Suzuki; K Kanamaru; H Tsunoda; H Inada; M Kuroki; H Sun; S Waga; T Tanaka
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

Review 6.  Current management of delayed cerebral ischemia: update from results of recent clinical trials.

Authors:  Shakira Brathwaite; R Loch Macdonald
Journal:  Transl Stroke Res       Date:  2013-12-13       Impact factor: 6.829

7.  Xenon-CT and transcranial Doppler in poor-grade or complicated aneurysmatic subarachnoid hemorrhage patients undergoing aggressive management of intracranial hypertension.

Authors:  Arturo Chieregato; Giuseppe Sabia; Alessandra Tanfani; Christian Compagnone; Fernanda Tagliaferri; Luigi Targa
Journal:  Intensive Care Med       Date:  2006-06-17       Impact factor: 17.440

8.  Milrinone as a rescue therapy for symptomatic refractory cerebral vasospasm in aneurysmal subarachnoid hemorrhage.

Authors:  C M Romero; D Morales; A Reccius; F Mena; J Prieto; P Bustos; J Larrondo; J Castro
Journal:  Neurocrit Care       Date:  2009       Impact factor: 3.210

9.  Inhibition of cerebral vasoconstriction by dantrolene and nimodipine.

Authors:  Salvatore Salomone; Guray Soydan; Michael A Moskowitz; John Randall Sims
Journal:  Neurocrit Care       Date:  2008-10-16       Impact factor: 3.210

Review 10.  Early brain injury, an evolving frontier in subarachnoid hemorrhage research.

Authors:  Mutsumi Fujii; Junhao Yan; William B Rolland; Yoshiteru Soejima; Basak Caner; John H Zhang
Journal:  Transl Stroke Res       Date:  2013-08       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.